KPV protocol
KPV (Lys-Pro-Val). The published work on this compound is animal or cell-culture research. No human dosing schedule exists to cite.
How KPV works
The C-terminal tripeptide of alpha-MSH. It carries the anti-inflammatory activity of the parent hormone without the pigmentation effects, and acts partly inside the cell on NF-κB signalling.
KPV dosing — what the literature actually supports
We publish a schedule when there is a citable human source and we say so when there is not. Filling this space with a number nobody measured would make the page look more complete and be worth less than nothing to you.
Reconstitution and measurement
This part is arithmetic and does not depend on the evidence level. Concentration is vial size divided by the bacteriostatic water you add. Draw volume is your target amount divided by that concentration. Units are draw volume times 100, because a U-100 syringe reads 100 units per millilitre. Common vials for KPV: 10 mg.
Storage and stability
Reported effects
- No human safety data from controlled trials.
- Rodent inflammation models report benefit at low amounts with little observed toxicity.
Sourcing KPV
Whatever you are working with, the documentation matters more than the price. Ask for a batch certificate of analysis whose lot number matches the vial you actually receive — a COA for a different batch tells you nothing about yours.
KPV at Summit Research Supply → Grade a COA first
Summit is the supplier we feature and an affiliate link. Our COA checklist applies the same way to any vendor.
